Cytokinetics Stock News

Majority of Initial Patients Enrolled in COURAGE-ALS Show Intended Middle to Fast Disease Progression Phenotype at Baseline Majority of Initial Patients Enrolled in COURAGE-ALS Show Intended Middle to

The FDA bestows a Breakthrough Therapy status on Cytokinetics' (CYTK) aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 29,166 shares of the businesss stock in a transaction dated Thursday, December 9th. The stock was sold at an average price of $36.49, for a total value of $1,064,267.34. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Fady []

FDA Granted Designation for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy Based on Results of REDWOOD-HCM FDA Granted Designation for the Treatment of Symptomatic Obstructive Hy

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome Acadia Pharmaceuticals Inc. (N

Zacks Investment Research lowered shares of Cytokinetics (NASDAQ:CYTK) from a hold rating to a sell rating in a report released on Friday, Zacks.com reports. According to Zacks, Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or []

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

Cytokinetics (NASDAQ:CYTK) had its price objective increased by Mizuho from $45.00 to $54.00 in a research note published on Wednesday morning, The Fly reports. Mizuho currently has a buy rating on the biopharmaceutical companys stock. CYTK has been the topic of several other research reports. HC Wainwright increased their target price on Cytokinetics from $58.00 []

Pinnacle Associates Ltd. cut its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 3.7% in the third quarter, Holdings Channel reports. The institutional investor owned 317,215 shares of the biopharmaceutical companys stock after selling 12,180 shares during the period. Pinnacle Associates Ltd.s holdings in Cytokinetics were worth $11,337,000 at the end of the most recent quarter. Other []

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2021 it granted stock options to purchase an aggregate o

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one oral presentation and three poster presentations at the 32nd Internationa

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one oral presentation and three poster presentations at the 32 nd International Symposium on ALS/MND taking place online from December 7 – December 10, 2021.

The moving averages on the daily timeframe suggest a bullishness in price, as the 20, 50, 100 and 200 are all in a bullish alignment -- meaning the shorter durations are above the longer duration averages, implying a sound upward trend. The post Cytokinetics Inc (CYTK): Price Down $-0.42 (-1.08)% Over Past Day, Down $-0.42 (-1.08)% Over Past Hour appeared first on ETF Daily News .

Invesco Ltd. boosted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 0.3% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 421,796 shares of the biopharmaceutical companys stock after acquiring an additional 1,284 shares during the quarter. Invesco Ltd. owned about 0.51% of Cytokinetics []

Cytokinetics Incorporated (NASDAQ:CYTK) shares, rose in value on Friday, 11/26/21, with the stock price down by -4.57% to the previous days close as strong demand from buyers drove the stock to $39.03. Actively observing the price movement in the last trading, the stock closed the session at $40.90, falling within a range of $38.10 and A Bullish 2021 Outlook For Cytokinetics Incorporated (NASDAQ: CYTK) Shares Read More »